Intelligent, Autonomous Analyte Monitoring and Insulin Dosing System

A wearable, implantable, or ingestible analyte monitoring system that integrates AI-driven predictive analytics with microneedle array-based sensing to provide real-time personalized recommendations for insulin dosing and lifestyle modifications.

The original patent, 'Fault detection for microneedle array based continuous analyte monitoring device', addressed the need for accurate and reliable analyte monitoring. However, it did not provide a comprehensive solution for personalized insulin dosing and lifestyle modifications. The new inventive concept addresses this limitation by incorporating AI-driven predictive analytics and real-time data analysis to provide a more holistic approach to diabetes management.

The system comprises a microneedle array-based sensor integrated with an AI module that utilizes machine learning algorithms to analyze the user's analyte levels, diet, exercise, and environmental factors. The AI module generates a dynamic, adaptive insulin dosing regimen tailored to the user's specific needs and provides real-time personalized recommendations for insulin dosing and lifestyle modifications. The system may also include a cloud-based server that utilizes blockchain technology to securely store and manage the user's sensor data, ensuring data integrity, confidentiality, and compliance with regulatory requirements. In addition, a next-generation microneedle array-based analyte monitoring device may be developed, featuring a bio-compatible, implantable sensor array, wireless communication module, and micro-encapsulated, controlled-release insulin delivery system.

The new claims introduce the concept of integrating AI-driven predictive analytics with microneedle array-based sensing, enabling real-time personalized recommendations for insulin dosing and lifestyle modifications. This represents a significant departure from the original patent, which focused solely on fault detection. The use of machine learning algorithms, blockchain technology, and autonomous insulin dosing systems further distinguishes the new inventive concept from existing solutions.

Alternative embodiments of the inventive concept may include variations in sensor design, AI module architecture, and data analysis algorithms. Additionally, the system could be adapted for use in other chronic disease management applications, such as cardiovascular disease or obesity management.

The intelligent, autonomous analyte monitoring and insulin dosing system has significant commercial potential in the diabetes management market, estimated to reach $12.6 billion by 2025. The system's ability to provide real-time personalized recommendations for insulin dosing and lifestyle modifications positions it as a game-changer in the industry, with potential applications in healthcare, pharmaceuticals, and medical devices.